DEF: Maze Therapeutics Sets 2026 Annual Meeting Date

Maze Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 8, 2026, to elect directors and ratify auditor appointment.

Summary

• Maze Therapeutics, Inc. is holding its 2026 Annual Meeting of Stockholders virtually on June 8, 2026, at 9:00 a.m. Pacific Time.
• The meeting will address two primary proposals: the election of Jason Coloma, Ph.D. and Neil Kumar, Ph.D. as Class I directors, and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• The record date for determining stockholders entitled to vote is April 13, 2026.
• Stockholders can attend and vote virtually by visiting www.virtualshareholdermeeting.com/MAZE2026.
• The company is a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for kidney and metabolic diseases using its Compass platform.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily focused on routine corporate governance matters and director elections, with no significant new financial or strategic information provided.

Positives

• The company is holding its annual meeting, indicating ongoing corporate operations and governance.
• The virtual format for the annual meeting is intended to increase accessibility and participation for stockholders.
• The board of directors is composed of a majority of independent directors, with all members of the audit and compensation committees being independent.
• The company has robust corporate governance practices, including risk oversight and regular board and committee evaluations.
• The company has adopted a Clawback Policy as required by Rule 10D-1 under the Exchange Act.

Risks

• The classification of the board of directors may have the effect of delaying or preventing changes in control of the company.

Future Outlook

The filing does not contain specific forward-looking financial guidance. It outlines the agenda for the upcoming annual meeting, which includes the election of directors and ratification of the independent auditor, and provides information on corporate governance and executive compensation.

Management Comments

• We invite you to attend the 2026 annual meeting of stockholders (the Annual Meeting) of Maze Therapeutics, Inc., a Delaware corporation, which will be held virtually on Monday, June 8, 2026 at 9:00 a.m., Pacific Time.
• We believe that a virtual stockholder meeting makes it easier for stockholders to attend and participate fully and equally in the Annual Meeting.
• We are committed to sound corporate governance, which strengthens the accountability of our board of directors and promotes the long-term interests of our stockholders.
• Every stockholder vote is important. Whether or not you plan to attend the Annual Meeting, please cast your vote as soon as possible by internet, telephone or mail to ensure your shares will be represented.

Industry Context

StockSavvy.ai notes that Maze Therapeutics is operating within the competitive clinical-stage biopharmaceutical sector, focusing on precision medicines for kidney and metabolic diseases. The company's reliance on its Compass platform for drug discovery and development is a key differentiator. The upcoming annual meeting is a standard corporate governance event for publicly traded companies in this industry.

Management Changes

Corporate Governance

Related Party Transactions

• Consulting agreement with Charles Homcy, M.D. (a director) for $240,000 per year, with additional stock options granted in April 2024 and December 2024.
• Convertible promissory notes financing from December 2023 to April 2024 included purchases by entities affiliated with directors and major stockholders (ARCH Ventures, Third Rock Ventures, GV, Charles Homcy, M.D.).
• Series D and Series D-1 Preferred Stock financing in November 2024 involved purchases by entities affiliated with directors and major stockholders (ARCH Ventures, Third Rock Ventures, GV, Charles Homcy, M.D.).
• Private Placement in September 2025 involved purchases by entities affiliated with major stockholders (Deep Track Capital, LP, Janus Henderson Group PLC, Frazier Life Sciences).

Stakeholder Impact

• Shareholders: The election of directors and ratification of the auditor directly impact corporate governance and oversight. The virtual meeting format aims to improve accessibility for all shareholders.
• Management: The election of directors confirms leadership continuity. Executive compensation details are provided, impacting management incentives.
• Employees: The company emphasizes competitive pay and benefits, ethical workplace behavior, and compliance with labor laws, indicating a focus on employee well-being and retention.

Next Steps

• Stockholders to vote on the election of directors and ratification of the independent auditor.
• The company will hold its virtual Annual Meeting of Stockholders on June 8, 2026.
• The company will file a Current Report on Form 8-K with the SEC to disclose voting results of the Annual Meeting.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting and does not contain new financial results, strategic updates, or material non-public information that would warrant a change in investment recommendation. It focuses on corporate governance and director elections. Therefore, a 'hold' recommendation is appropriate based solely on this document.

Keywords

Maze Therapeutics, Proxy Statement, Annual Meeting, Stockholders, Director Election, Independent Auditor, Biopharmaceutical, Clinical Stage, Kidney Disease, Metabolic Disease, Corporate Governance